Incyte (ICY) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Incyte CH:ICY is currently developing the following drugs: Inca033989, Best Available Treatment, Ruxolitinib, Povorcitinib, Incb054707, Incb161734, Investigator's Choice Of Chemotherapy, Mfolfirinox, Gemnabp, Inca033989, Standard Disease-Directed Therapy, Inca036978, Bevacizumab, Folfox, Inca33890, Incb123667, Povorcitinib, Incb123667, Investigator's Choice Of Chemotherapy, Inca036873, Inca034176, Best Available Treatment, Inca000585, Ruxolitinib Cream, Incb000631, Itraconazole, Famotidine, Esomeprazole, Rifampin, Incb161734, Inca035784, Vehicle Cream, Ruxolitinib Cream, Incb057643, Retifanlimab, Incb177054, Inca034176, Best Available Therapy, Inca034176, Cetuximab, Mfolfirinox, Incb186748, Gemnabp, Vehicle Cream, Ruxolitinib, Axatilimab, Cyclophosphamide, Methotrexate, Mycophenolate Mofetil, Tacrolimus, Ruxolitinib, Corticosteroids, Inca034176, Ruxolitinib Ir, Ruxolitinib Xr, Tafasitamab, Rosuvastatin, Metformin, Digoxin, Probenecid, Povorcitinib, Corticosteroids, Ruxolitinib, Axatilimab, Incb160058. These drug candidates are in various stages of clinical development as the company works toward FDA approval.